InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 349 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... December 5, 2019 Terminally Ill ‘Flamingo Lady’ Gets Emotional After Dying Wish Comes True September 27, 2021 ESMO AI & Digital Oncology Congress 2025 Closed in Berlin under... November 17, 2025 Load more HOT NEWS Patient Guide in Testicular Cancer Now Available Also in Italian Doing More—Together—to End Cancer as We Know It One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early?
